Pressure and Pain In Systemic Sclerosis/ Scleroderma PDF Print E-mail
Saturday, 18 February 2012 12:10
Begonya Alcacer-Pitarch, Maya H Buch, Janine Gray, Christopher P Denton, Ariane Herrick, Nuria Navarro-Coy, Howard Collier, Lorraine Loughrey, Sue Pavitt, Heidi J Siddle, Jonathan Wright, Philip S Helliwell, Paul Emery, Anthony C Redmond
Study protocol, Submitted 14 December 2011, Accepted 6 February 2012, Published 6 February 2012

Foot problems associated with Systemic Sclerosis (SSc)/Scleroderma have been reported to be both common and disabling. There are only limited data describing specifically, the mechanical changes occurring in the foot in SSc. A pilot project conducted in preparation for this trial confirmed the previous reports of foot related impairment and reduced foot function in people with SSc and demonstrated a link to mechanical etiologies. To-date there have been no formal studies of interventions directed at the foot problems experienced by people with Systemic Sclerosis. The primary aim of this trial is to evaluate whether foot pain and footrelated health status in people with Systemic Sclerosis can be improved through the provision of a simple pressure-relieving insole.

The proposed trial is a pragmatic, multicenter, randomised controlled clinical trial following a completed pilot study. In four participating centres, 140 consenting patients with SSc and plantar foot pain will be randomised to receive either a commercially available pressure relieving and thermally insulating insole, or a sham insole with no cushioning or thermal properties. The primary end point is a reduction in pain measured using the Foot Function Index Pain subscale, 12 weeks after the start of intervention. Participants will complete the primary outcome measure (Foot Function Index pain sub-scale) prior to randomisation and at 12 weeks post randomisation. Secondary outcomes include participant reported pain and disability as derived from the Manchester Foot Pain and Disability Questionnaire and plantar pressures with and without the insoles in situ.

Continue reading the full study protocol, by downloading it from the link provided below.

 
More articles :

» Anticoagulation of Systemic Sclerosis Patients In Question

Australia is in a state of ‘clinical equipoise’ over whether to anticoagulate systemic sclerosis patients with pulmonary hypertension, experts say. And with observational studies showing the treatment is associated with a  fivefold...

» PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers: Current Status of Clinical Trials

Ann J. Impens, Kristine Phillips, and Elena SchiopuReceived 2 June 2011; Accepted 2 August 2011Phosphodiesterases (PDEs) are isoenzymes that control the level of intracellular cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate...

» New Understanding of Skin Hardening Syndromes Found

New details about the underlying mechanisms of skin hardening syndromes, morphea, have been discovered by researchers from (BUSM). Morphea, also known as localized scleroderma, is a disorder characterized by leading to thickening of the dermis,...

» Making A Difference

, a Center for Student Missions team member, recently recounted a touching experience, in which she heard about and met someone with Scleroderma for the very first time. According to Jessica, "We don't always get to see the effect of what it is we...

» Important Information About Autoimmune Diseases

There are more than 100 known autoimmune disorders, including rheumatoid arthritis, type 1 diabetes, scleroderma, and lupus. Normally, your immune system is designed to protect your health. But in some people, the immune system creates...

» arGentis Continues To Expand

But arGentis grew its drug-development pipeline this month with the acquisition of the rights to a rheumatoid arthritis therapy from the - the terms of which, were not disclosed. The treatment was developed at the University of Tennessee Health...